Strategy analysis

China Regulatory Update

China has recently completed its 2009–11 healthcare reform. The reform has come at a high cost: although the Ministry of Health intended to invest CNY850bn ($135bn) in the plan, total investment has now exceeded CNY1,100bn ($175bn).

November 4, 2016

Disruptive Innovation and the Pharmaceutical Contract Services Sector

$5,000.00

With the pharmaceutical sector currently in the middle of such a transformative cycle, are drug developers or the firms providing them with outsourced research or manufacturing services going to find themselves similarly left behind?

November 3, 2016

Big Pharma Licensing Trends, 2012–16

Between 2012 and 2016, Big Pharma – a peer set of approximately 16 firms across the world with large R&D and sales organizations, and annual revenues in excess of $10bn – signed over 1,200 drug-focused deals, growing at a compound annual growth rate of 12%.

March 8, 2017

Rheumatoid Arthritis KOL Interview – California, US

A US-based key opinion leader provides insights into prescribing habits, the most pressing unmet needs in the market, the role of biosimilars, key marketed brands, and late-phase pipeline therapies for rheumatoid arthritis, including upadacitinib and filgotinib.

July 31, 2019

Digital Pharma: Are We Nearly There?

Digital’s potential to transform every aspect of the pharmaceutical value chain, from discovery to commercial, is widely documented.

August 14, 2018

France Generics and Biosimilars

Traditionally considered an immature generics market, France has seen the introduction of measures aimed at increasing generics use in order to cut healthcare costs.

November 3, 2016

Bladder Cancer KOL Interview – US

A US KOL provides insight into the current treatment landscape for bladder cancer. Critical unmet needs in the bladder cancer market along with future trends are also discussed.

May 31, 2019

Datamonitor Healthcare Strategy: Immuno-Oncology Deal Trends, 2014–18

Immuno-oncology continues to draw pharma companies to the deal table.

August 5, 2019

From R&D Investment to Externalization: Where is the Pharma Industry Maximizing Value?

Pharmaceutical companies are attempting to maximize value from all angles, including internal investment in R&D and externalization via deal-making.

June 8, 2017

Hemophilia Pricing, Reimbursement, and Access

Over the last two decades, clinical care of hemophilia has improved significantly, extending the life expectancy for this patient population closer to that of the general population. The emergence of virally inactivated plasma-derived clotting factors and then of recombinant clotting factor replacement therapy in the 1980s has revolutionized care for these patients.

January 18, 2017

NASH KOL Insight Interview #2

KOL Highlights Include: The prevalence of cirrhosis due to NASH will far exceed that of cirrhosis due to Hepatitis C. Decreases in NAS score due to liver fat changes are not predictive of beneficial outcomes. Increasing LDL in patients with fatty liver disease is a concern. Results seen in animal models of NAFLD/NASH translate to […]

March 4, 2014

Datamonitor Healthcare HIV KOL Interview – US #2

A US key opinion leader (KOL) provides insights into the HIV treatment market, including a discussion on prescribing trends, key marketed therapies, impact of generic launches, and pipeline therapies.

January 25, 2019

Value-Based Reimbursement in the US

The US healthcare environment has been witnessing a slow albeit continuous shift from volume- to value-based reimbursement over the past couple of decades

August 22, 2018

Prostate Cancer KOL Interview – UK #1

A UK-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for prostate cancer. Key pipeline assets highlighted include Keytruda, Tecentriq, Opdivo, ipatasertib, capivasertib, and Lutetium 177Lu-PSMA-617.

February 9, 2022